Mirtazapine Eg (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising serotonin 5‑HT2 and 5‑HT3 receptors. This dual action raises overall serotonin and norepinephrine activity in the brain, producing an antidepressant effect.

The dose of Mirtazapine Eg is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Safety data for Mirtazapine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare professional.

To order Mirtazapine Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine often produces more sedation and weight gain but may be better tolerated in patients who experience sexual dysfunction or gastrointestinal side effects with SSRIs. Both classes are effective for depression, and choice depends on individual patient factors.

Mirtazapine Eg should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Mirtazapine Eg is administered orally, usually once daily in the evening because of its sedative effect. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber.

Serious risks include agranulocytosis or severe neutropenia, hepatic dysfunction, and the emergence of suicidal thoughts or behaviors, especially during the initial weeks of therapy. Patients should seek immediate medical attention if they notice signs of infection, jaundice, or worsening mood.

Mirtazapine Eg should not be used by individuals with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or patients with severe hepatic impairment. Contraindications and precautions must be reviewed by a healthcare professional before initiating therapy.